MOTS-c

MOTS-c is a 16-residue peptide whose sequence is conserved across mammals and translated from a small open reading frame within the 12S rRNA region — a feature that distinguishes mitochondrial-derived peptides from canonical nuclear-encoded signaling molecules. The molecule's interaction profile in the literature centers on AMPK-pathway activation, with downstream investigations of glucose homeostasis, fatty-acid oxidation regulation, and mitochondrial-biogenesis markers in cell-culture and rodent-model contexts. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance under standard parenteral paradigms and short systemic residence. All activity descriptors here are framed as documented in published work rather than as effects of the supplied product. Structural confirmation of supplied lots is established by mass spectrometry molecular-ion match to the C101H152N28O22S2 empirical formula, with HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include AMPK-pathway signaling assays, in-vitro glucose-uptake studies in muscle and adipocyte cell models, mitochondrial-biogenesis-marker investigations, fatty-acid-oxidation pathway analysis, and comparative work alongside other mitochondrial-derived peptides in metabolic-stress paradigms. Investigators have also characterized MOTS-c in studies of mitochondrial-nuclear retrograde signaling and in age-related metabolic-pathway research. Use in laboratory research extends to mechanism-elucidation paradigms where the literature frames MOTS-c as a probe for mitochondrial-derived signaling rather than as a defined intervention. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature when designing context-specific protocols.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C101H152N28O22S2 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.